business / news / / Barchart
Merck & Co., Inc. (MRK) offers human health pharmaceuticals across various areas.
Merck's acquisition of Terns Pharmaceuticals was for $53 per share, totaling $6.7 billion.
KEY POINTS
- The Terns acquisition expands Merck's hematology portfolio specifically with the TERN-701 molecule.
- Analysts expect Merck's EPS to decline by 45.4% to $4.90 for the current year.
- Merck stock has outperformed both the S&P 500 and healthcare sector ETF XLV over the last year.
- MRK's highest analyst price target is $150, implying a possible 33.7% upside from current prices.
COMPANIES
Summarized by Newsio from Barchart. How we summarize →